Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1441-1449

  Markosyan, Nune ^a   Chen, Edward P ^a   Ndong, Victoire N ^a   Yao, Yubing ^a   Sterner, Christopher J ^b   Chodosh, Lewis A ^b   Lawson, John A ^a   FitzGerald, Garret A ^a   Smyth, Emer M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; CD45 ANTIGEN; CD86 ANTIGEN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GENOMIC DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; PROSTAGLANDIN E2; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER PREVENTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE DELETION; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAMMARY GLAND; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, WESTERN; CARCINOGENS; CELLS, CULTURED; CONTRACEPTIVES, ORAL, SYNTHETIC; CYCLOOXYGENASE 2; CYTOKINES; EICOSANOIDS; EPITHELIAL CELLS; FEMALE; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; MACROPHAGES; MACROPHAGES, PERITONEAL; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDROXYPROGESTERONE; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS;

EID: 80053137426     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr134     Document Type: Article

References (51)

1. Harris,R.E. (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17, 55-67.
2. Howe,L.R. (2007) Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res., 9, 210.
3. Arun,B. et al. (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol., 31, 22-9.
4. Howe,L.R. et al. (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neuinduced breast cancer. Cancer Res., 62, 5405-5407.
5. Lanza-Jacoby,S. et al. (2003) The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol. Biomarkers Prev., 12, 1486-1491.
6. Howe,L. et al. (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res., 65, 10113-10119.
7. Liu,C.H. et al. (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276, 18563-18569.
8. Cuzick,J. et al. (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol., 10, 501-507.
9. Harris,R. et al. (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 6, 27.
10. Solomon,S. et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 352, 1071-80.
11. Solomon,S. et al. (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114, 1028-1035.
12. Grosser,T. et al. (2010) Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med., 61, 17-33.
13. Wang,D. et al. (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res., 65, 1822-1829.
14. Buchanan,F.G. et al. (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem., 278, 35451-35457.
15. Sheng,H. et al. (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58, 362-366.
16. Castellone,M. et al. (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310, 1504-1510.
17. Chang,S. et al. (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl Acad. Sci. USA, 101, 591-596.
18. Joyce,J.A. et al. (2009) Microenvironmental regulation of metastasis. Nat. Rev. Cancer, 9, 239-252.
19. Hanahan,D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
20. Erez,N. et al. (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaBdependent manner. Cancer Cell, 17, 135-147.
21. Pollard,J. (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer, 4, 71-78.
22. Hu,M. et al. (2009) Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl Acad. Sci. USA, 106, 3372-3377.
23. Hou,Z. et al. (2011) Macrophages induce COX-2 expression in breast cancer cells: role of IL-1{beta} auto-amplification. Carcinogenesis.
24. Okano,M. et al. (2006) E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology, 118, 343-352.
25. DeNardo,D.G. et al. (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev., 29, 309-316.
26. Wang,D. et al. (2010) Eicosanoids and cancer. Nat. Rev. Cancer, 10, 181-193.
27. Eruslanov,E. et al. (2010) Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J. Leukoc. Biol., 88, 839-848.
28. Wang,D. et al. (2009) Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc. Natl Acad. Sci. USA, 106, 7548-7552.
29. Narko,K. et al. (2005) COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins Other Lipid Mediat., 76, 86-94.
30. Sinha,P. et al. (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol., 174, 636-645.
31. Song,W. et al. (2007) Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol., 433, 51-72.
32. Bookout,A. et al. (2003) Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal, 1, e012.
33. Yan,D. et al. (2004) A delayed chemically induced tumorigenesis in Brca2 mutant mice. Oncogene, 23, 1896-1901.
34. Martinez,F.O. et al. (2008) Macrophage activation and polarization. Front. Biosci., 13, 453-461.
35. Nakayama,M. et al. (2009) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood, 113, 3821-3830.
36. Nakae,S. et al. (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukoc. Biol., 81, 1258-1268.
37. Grösch,S. et al. (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst., 98, 736-747.
38. Pradono,P. et al. (2002) Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res., 62, 63-66.
39. Kim,J. et al. (2005) Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res., 65, 6189-6198.
40. Vergote,I. et al. (1985) Prostaglandin F2 alpha in benign and malignant breast tumours. Br. J. Cancer, 51, 827-836.
41. Sivula,A. et al. (2005) Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res. Treat., 89, 215-220.
42. DeNardo,D.G. et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16, 91-102.
43. Mantovani,A. et al. (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev., 25, 315-322.
44. Leek,R. et al. (2002) Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia, 7, 177-189.
45. Gouon-Evans,V. et al. (2002) Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res., 4, 155-164.
46. Mantovani,A. et al. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol., 23, 549-555.
47. van der Bij,G. et al. (2008) Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett.
48. Kim,D. et al. (2008) High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br. J. Cancer, 98, 1118-1124.
49. Jadus,M. et al. (1996) Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. Blood, 87, 5232-5241.
50. Yao,C. et al. (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med., 15, 633-640.
51. Boniface,K. et al. (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med., 206, 535-548.